Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > 13 G filing

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 14, 2022 5:21pm

77 Views

Post# 35098049

RE:RE:RE:RE:13 G filing

No impact imo but maybe Wino could look at it
Am at Mco right now snd not much time

palinc2000 wrote:

My understsnfing is that the Filing is simply to account for the transfer of the shsres ftom Soleus to a General Partner controlled by Soleus

palinc2000 wrote: [The 9.5 mil'ion includes 1555000 warrabts

quote=palinc2000]

Seems like Soleus hold 9.5 million shares representing 10.1 %

palinc2000 wrote: Soleus